- Researchers have learned more about how increased levels of an enzymatic protein called HDAC6 connects to the onset of harmful brain changes in Alzheimer’s disease (AD)
- In modeling studies, they identified several pathways through which drugs designed to inhibit HDAC6 activity could help—by reducing the accumulation of harmful plaques and tau, lowering inflammation and more
- The findings suggest further investigation of HDAC6 inhibitors—including one developed by the research team—as potential pharmacological treatment for AD patients
BOSTON—In people with Alzheimer’s disease (AD), the epigenetic regulator HDAC6 (histone deacetylase 6), which controls many biological processes, is significantly overexpressed in the brain.
Evidence suggests that HDAC6 is closely related to amyloid and tau pathology, the two primary hallmarks of AD.
But it has been unclear whether the amyloid deposits in AD change with elevation of HDAC6 expression as the disease progresses; or whether HDAC6 itself regulates neuroinflammation and other neuropathological changes in AD.
Researchers at Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham healthcare system, recently used a series of chemical and biological studies in disease-specific cell lines to learn more about the role of HDAC6 in AD and how new therapeutics designed to inhibit its activity that could reduce pathology of the disease. The results of this work are published in Advanced Science.
“We continue to lack effective and safe treatments that can prevent, stop, or reverse AD progression largely due to the complex etiology of AD,” said senior author Can (Martin) Zhang, MD, PhD, an investigator at the McCance Center for Brain Health at Massachusetts General Hospital. “Collective data suggest that we need new angles and alternative approaches.”
Our present study leverages our cross-disciplinary team’s rich expertise on the neuropathology of AD, biochemistry, cell and molecular biology to characterize a target for drug discovery in AD.
Can Zhang, MD, PhD
Among the cellular functions that HDAC6 controls are cell proliferation, immune response, stress response, neurological changes, and clearance of misfolded proteins.
When HDAC6 is dysfunctional, abnormal cellular responses result, leading to pathology. HDAC6 has been implicated in multiple diseases, including cancer and neurodegenerative diseases. Currently, drugs that inhibit HDAC6 are being evaluated in clinical trials for the treatment of cancer, for example.
The role of HDAC6 in the neurodegeneration of AD, as well as that of other epigenetic proteins, is less well explored, however.
To address this, the investigators sought to analyze the effects of the harmful accumulation of HDAC6 in the brain of a mouse model of AD and looked at how HDAC6 changed as the disease pathology started to progress in early stages.
“In this work, we have seen both amyloid deposits and HDAC6 levels become elevated in mouse models of AD as the mice age, suggesting both factors may combine to impair the clearance of amyloid beta (Aβ) from the brain and contribute to the damaging effects of the disease,” said lead author Prasenjit Mondal, PhD, senior postdoctoral research fellow at Massachusetts General Hospital.
Our results in the lab motivated us to design a novel small-molecule inhibitor of HDAC6 that would serve as a potential therapeutic against AD.
Changning Wang, PhD
Department of Radiology, Mass General
The investigators found that their HDAC6 inhibitor, called PB118, cleared amyloid-beta deposits through several mechanisms, including reducing Aβ production, increasing the uptake of Aβ from the brain, improving the tubulin/microtubule network disrupted in AD, regulating different cytokines and chemokines responsible for inflammation, and significantly reducing tau phosphorylation associated with AD.
In ongoing research, the investigators are developing an inhibitor molecule that binds strongly and exclusively to HDAC6 and not to additional proteins. They are also studying whether the inhibitors have the potential to suppress the neuropathological changes of Alzheimer’s disease in mice.
In addition, the research team has developed a new positron emission tomography (PET) imaging probe that can detect increased HDAC6 levels in the brain to potentially serve as an imaging biomarker of AD.
Additional authors include Rudolph E. Tanzi, Se Hoon Choi, Ping Bai, Ashley Gomm, Grisilda Bakiasi, Chih-Chung Jerry Lin, and Yanli Wang.
This work was supported by pilot funding from the Athinoula A. Martinos Center for Biomedical Imaging and the Cure Alzheimer’s Fund.
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments.